Object. Complete resection is the optimal treatment for atypical meningiomas (AMs) but its feasibility depends on the tumor site. The object of this study was to assess the effect of gamma knife surgery (GKS) on AM.
benign meningiomas have a recurrence rate of 90 and 75% at 5 and 10 years, respectively, after complete resection of the tumor and its dural base, 18 aggressive resection is not always possible. In addition WHO Grade II AMs have higher rates of recurrence, 13, 20 progression, morbidity, and mortality. 12 Microsurgery has been the primary treatment modality for meningiomas, regardless of subtype. The extent of surgery is important for predicting the risk of recurrence and possibly defines the need for adjuvant therapy. 5 Radiotherapy after resection of benign and AMs continues to be controversial. 3 Because of the rarity of AMs and differences in the way they were classified, the literature on the role of radiation is difficult to interpret. As a result, the treatment has largely been extrapolated from data on both benign and malignant meningiomas.
Gamma knife surgery has proven beneficial in the treatment of benign meningiomas, both as an adjunct to subtotal resection and as a primary treatment for selected patients. 1, 10, 19 Relatively few published studies have defined the role of GKS for AM. In the series by Stafford, et al., 19 the cause-specific survival rate for patients with benign meningiomas was 100% compared with 83% for patients with AM. The authors presumed the tumor histological type as probably the most important factor associated with failed meningioma radiosurgery. Harris, et al., 4 indicated that stereotactic radiosurgery was an important early adjuvant management strategy for focal residual or recurrent AM.
In this study we report the results in 15 patients with residual or recurrent AM treated with GKS.
Clinical Material and Methods
Fifteen consecutive patients with 21 AMs underwent GKS at the University of Aachen between 1998 and 2002. The data were collected in a prospectively maintained database. In all but one patient AM was histologically confirmed. For the term atypical to be used a mitotic rate of at least four mitotic figures per 10 hpf was the most important feature, yielding confirmation of atypia in the absence of the other features (such as increased cellularity; small cells with a high nucleus/cytoplasm ratio; prominent nucleoli; sheet AMs like growth pattern; and "geographic" necrosis). In the absence of this mitotic rate at least three of the other five features had to be present for a histological diagnosis of atypia, WHO Grade II. In one patient a parasagittal meningioma was treated without histological verification after surgery of a remote convexity AM. Two patients had a meningioma that had progressed from an initial benign pathological entity to an atypical histology defined at the time of reoperation; in one at reoperation for a recurrent tumor at the margin after GKS.
Fourteen patients harbored one tumor, one patient two tumors, and three patients were treated twice with GKS, two for a margin and one for three distant recurrences. Therefore, a total of 21 tumors were treated in 15 patients. A median of one (range one-two) GKS procedures was performed per patient. All repeated radiosurgery procedures were for recurrent tumor. Tumor locations are presented in Table 1 .
There were nine women and six men whose median age at the time of radiosurgery was 51 years (range 30-75 years). In 12 patients the Karnofsky Performance Scale score was greater than or equal to 80. Four patients had residual disease, and 10 recurrent tumors after one or more previous operations (median two; range one-four). One patient underwent EBRT after microsurgery and before GKS.
Radiosurgery was performed using a Leksell Gamma Knife model B (Elekta Instrument AB, Stockholm, Sweden). Multishot-dose plans were created to construct a radiation field conformal with the often irregularly shaped tumors. Treatment planning was performed using Leksell Gamma Plan (Elekta Instrument AB). Standard techniques 2 for GKS planning were used. Prescription doses were based on tumor volume, location, and previous irradiation. Because WHO Grade II tumors are associated with a higher rate of recurrence (29-40%) than WHO Grade I tumors (7-20%), 11 we tried to prescribe higher radiation doses than those for benign meningiomas in the hope of achieving better tumor control in cases involving more aggressive AMs; however one patient had previously undergone EBRT and others will probably undergo EBRT for recurrent post-GKS tumor. Therefore the prescription dose was limited to 18 Gy to reduce the incidence of symptomatic radiation-induced necrosis. Depending on tumor volume and adjacent radiosensitive structures, a margin dose of 18 Gy could be administered in only 12 tumors. The other AMs were treated with prescription doses between 14 and 16 Gy. Thus, the median prescription dose was 16 Gy (range 14-18 Gy); the median maximum dose was 32 Gy (range 28-36 Gy); and the median target volume was 5 cm 3 (range 0.4-13 cm 3 ). The median neuroimaging and clinical follow-up period was 35 months (range 21-67 months). Patients were instructed to undergo MR imaging every 6 months after radiosurgery. Follow-up MR images were compared with images obtained the day of radiosurgery. In each case, the tumor diameters in the x, y, and z planes were determined, and the MR images were reviewed for evidence of adverse radiation-related effects. Tumor sizes were classified as unchanged, decreased, or increased. Tumor growth adjacent to the irradiated tumor and outside the prescription isodose volume was defined as a margin recurrence. Tumors developing in noncontiguous sites were considered distant recurrences. The performance status of each patient was described as unchanged, improved, or worse on the basis of the patient's current performance status compared with that at the time of radiosurgery.
Results
At 6-month follow up, 11 patients remained clinically stable without change in neurological signs or symptoms. Three patients improved clinically, with two suffering fewer headaches; one patient was free from epileptic seizures without medication. Smaller tumors in these patients were demonstrated on follow-up MR images. The patient who had previously undergone postoperative EBRT exhibited tumor progression 6 months after radiosurgery; he underwent two additional resections and died 39 months after GKS. No new specimen could be obtained to examine the histological grade of the meningioma again.
Thus one tumor had increased, 10 were unchanged, and 10 had decreased. Shrinkage of AM at 6 to 12 months after treatment is shown in Fig. 1 .
Between 18 and 36 months after GKS four patients had developed a distant and two a tumor margin recurrence. All distant recurrences developed in the region of the surgical approach or resection. In one of the patients with distant recurrent tumor treated with a prescription dose of 15 Gy, an additional local (in-field) recurrence was demonstrated 2.3 years after GKS as shown in Fig. 2 and underwent EBRT for both tumors (54 Gy); however, the AMs continued to grow and both had to be reresected. All but one patient with recurrent tumor were treated with prescription doses less than 18 Gy.
Three patients underwent repeated GKS, two for margin and one for three distant recurrences. In the last two patients distant recurrent AMs had to be resected because their volumes were already too large for radiosurgery. One of these tumors recurred again after 4 months. None of these patients with residual postoperative tumor treated with GKS showed an in-field or marginal tumor growth or return. Recurrent AMs were only found in patients with smaller tumor soon after GKS.
No persistent adverse effects occurred. One patient presented with a peritumoral edema with hemiparesis and focal epileptic seizures 3 months after GKS. The edema and clinical deterioration resolved completely during 6 months. This patient had exhibited the same symptoms after each of two previous tumor resections.
Discussion

Recurrence Rates in the Literature
In the new WHO classification of tumors of the nervous system, the histopathological criteria of WHO Grade II AMs are now precisely defined. 17 It divides meningiomas into three categories, each with different recurrence rates.
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Prior to this it was difficult to classify meningiomas into aggressive varieties. Several studies used the scoring system of Jäaskelainen, et al., 7 to classify these tumors. Others have used different classification systems. They examined the clinical course of atypical and malignant meningiomas after complete or partial surgery, possibly with additional adjuvant EBRT. In a series by Jäaskelainen and coworkers, 8 the authors reported a 5-year recurrence rate for AMs of 38%. Maier, et al., 13 described recurrence rates of 34% in contrast to classic meningiomas with a rate of 6.9%. Palma, et al., 16 reported that patients with AM had significantly better outcomes in terms of cumulative survival, recurrencefree survival, and median time to recurrence during a longterm follow-up period than did patients with malignant meningiomas; however, when they considered only cases involving incomplete resection the survival curve of AMs was not significantly better than that of malignant meningiomas. They and other authors found that only radical extirpation and histological grade were related to survival.
Stereotactic Radiosurgery
Because gross-total resection is not always possible, we used adjuvant GKS for residual or recurrent AM in our study. Our preliminary results indicate no recurrence of residual tumor treated with GKS. Harris, et al., 4 found that "early GKS" (treatment was given soon after craniotomy in the absence of neuroimaging-documented disease progression) was a significant predictor of better progression-free survival. They advocated radiosurgery as an up-front boost to EBRT to improve outcomes. In their study and the report of Ojemann, et al., 15 for malignant meningiomas, it was found that greater tumor volumes influenced the progression-free survival negatively. We only irradiated AM with a volume up to 13 cm 3 and a median volume of 5 cm 3 . No persistent adverse effects occurred. Thus, residual small-and medium-sized AM should be treated soon after resection with GKS. The role of EBRT after GKS of residual tumors must still be discussed because few studies with small patient populations have been published.
Between 18 and 36 months after GKS of recurrent AM six of 15 patients (40%) had distant or marginal recurrent tumors; in one case there was an additional in-field recurrence after 2.3 years. All recurrent AMs had at first become smaller. Thus, after early tumor shrinkage high recurrence rates were associated with margin or distant locations despite the use of GKS. The lower in-field recurrence rate of tumors compared the incidence cited in the literature 19 could be due to our higher prescription doses of 18 Gy, or the short follow-up period of 21 to 67 months. Limitations of the current study include the small patient population and a relatively short median follow-up time of 35 months. The only patient with a local relapse was treated with a prescription dose of 15 Gy.
In contrast to benign meningiomas 10 of 21 tumors significantly decreased 6 to 12 months after radiosurgery, and only these tumors recurred, probably because of the "proliferative potential" 9 Because two recurrent AMs had already grown too large for radiosurgery during a 6-month follow-up period, perhaps AM that decrease should be examined every 3 months.
Adjuvant Radiotherapy
Recurrent tumors were located marginal to or distant from the region of surgical approach or resection in our study. Therefore, after complete resection and adjuvant fractionated EBRT should be considered. Based on review of the literature no conclusions regarding therapeutic benefits can be drawn because of the small number of patients undergoing fractionated EBRT. 12 Although Milosevic, et al., 14 reported improved local control for atypical and malignant meningiomas when radiation doses were over 50 Gy, in other studies 3 the numbers were not large enough to draw any conclusions with regard to radiation dose and treatment outcome. Hug, et al., 6 also described that most reports are based on only small populations, retrospectively reviewed data, and data often collected over several decades, thereby pre-dating in part modern imaging and treatment techniques. We found that the definition of histological "malignancy" varies greatly throughout the literature. In the majority of reports, radiotherapy is recommended for all malignant meningiomas regardless of whether resection was total or subtotal. It is important to balance the risks of aggressive treatment (with possible complications such as radiation necrosis) with the risks of conservative treatment (with suboptimal tumor control and poor clinical outcomes). 4 We propose early GKS for incompletely resected residual AMs. For gross totally resected tumors, fractionated EBRT should be considered. If focal recurrences develop after resection or margin or distant recurrent AM develop after radiosurgery, GKS is an alternative to repeated microsurgery.
Conclusions
Patients with AMs continue to exhibit high recurrence rates despite aggressive treatment including surgery, EBRT, and radiosurgery. After GKS, early tumor shrinkage occurred. Tumor recurrence was essentially outside the GKS radiation field. Preliminary results indicate that GKS may have a place as an adjunct to treatment for residual or recurrent small-and medium-sized AMs.
